Latest news with #Abbvie
CNBC
01-05-2025
- Business
- CNBC
Three Stock Lunch: AbbVie, UnitedHealth, and Booking Holdings
Chris Grisanti, MAI Capital Management, joins 'Power Lunch' to discuss Gristanti's investing take on three stocks: Abbvie, UnitedHealth, and Booking Holdings.
Forbes
28-04-2025
- Health
- Forbes
Health Plans Brace For Cell And Gene Therapy Costs
Cell and gene therapies are breaking ground as life-saving treatments, but their six- and seven-figure price tags are an increasing worry for employers and healths, according to a new analysis. More than 70% of employers and health plans expect affordability of gene therapy for their health plan members and workers will be a 'moderate or major challenge' over the next 2 to 3 years, according to a report released Monday at Asembia ASX25 in Las Vegas by Pharmaceutical Strategies Group (PSG). The analysis was based on responses from more than 230 health benefits executives from health plans, employers and unions. The report comes with up to a dozen new cell and gene therapies expected to launch on the U.S. market this year, PSG's report said. Such therapies, which can 'prevent or treat a disease by adding, replacing, or turning off genes,' come with high prices such as $475,000 for a treatment for acute lymphoblastic leukemia or more than $3 million for a treatment for hemophilia B. Yet despite the headline-grabbing costs of some of these new treatments, those picking up the tab for the bulk of the costs aren't prepared for potential expenses to their budgets for healthcare. Even though 73% of plans expect cell and gene therapies to 'pose a moderate or major financial challenge in the next 2–3 years, most express low confidence in their understanding of the financial impact,' PSG said in a statement accompanying its report. 'What's more, nearly 40% don't currently use any financial protection product to manage their financial risk related to cell and gene therapies.' 'These therapies aren't one-size-fits-all,' said Renee Rayburg, vice president of clinical strategy at PSG. 'Not only do gene therapies present financial challenges, they're also complex in terms of which patients are eligible as well as the treatment process, and demand is higher for some gene therapies than others. Payers need expert analysis that considers their population, pipeline exposure, and vendor ecosystem.' Specialty drugs already account for well more than half of the total prescription spending any health plan, employer or government health program manages. Employer clients tell benefits consultants specialty costs easily account for 60% or more of their total drug spending, particularly as more Americans flock to anti-obesity GLP-1 medicines, prescriptions hailed for their ability to help people lose weight. But the PSG report says employers are increasingly finding ways to deal with specialty drugs. Take Humira, for example, an expensive rheumatoid arthritis drug derived from biotechnology that at its peak generated more than $20 billion in annual sales as the world's top selling drug for its maker, Abbvie. Humira costs more than $50,00o a patient. But increasingly health plans and employers are covering less expensive biosimilar versions of Humira in a 'preferred position' in their preferred list of drugs known as formularies. The PSG report said '65% of plans have implemented a preferred drug strategy for one or more Humira biosimilars.' 'Leaders are eager to try new approaches to address costs while preserving access to drugs that their members need,' said PSG's chief operating officer, Rebekah Gregg. 'Yet many benefit leaders lack the data, infrastructure, and confidence to fully implement those strategies. Transparency and clear, data- driven insights will be vital to adapt to the pressures payers face.'
Globe and Mail
03-04-2025
- Health
- Globe and Mail
Cerebral Palsy Market Growth Projections 2024-2034: DelveInsight Analysis
The Key Cerebral Palsy Companies in the market include - Ipsen, Abbvie (Allergan), Supernus Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Bundang CHA Hospital, Jazz Pharmaceuticals, Stanford University, Teva Branded Pharmaceutical, Merz Pharmaceuticals GmbH, Rohto Pharmaceutical Co., Ltd., Shionogi, and others. DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cerebral Palsy, historical and forecasted epidemiology as well as the Cerebral Palsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Cerebral Palsy Market Report: The Cerebral Palsy market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, GeneDx (Nasdaq: WGS), a leading provider of genomic insights for better health outcomes, has announced the expansion of its genetic testing services to include cerebral palsy (CP). Timed with Cerebral Palsy Awareness Month, this initiative broadens the company's focus on pediatric rare diseases by offering testing for children with CP. The expansion highlights the importance of enhancing access to exome and genome testing, aiming to reduce diagnostic delays and expedite treatment pathways for CP patients. The cerebral palsy market is projected to experience steady growth, with a strong compound annual growth rate (CAGR) expected from 2024 to 2034. This growth across the 7MM is fueled by the launch of new therapies like MYOBLOC and UDI-001, as well as improvements in genetic testing and diagnostic methods. According to DelveInsight's epidemiology model, there were roughly 1.9 million prevalent cases of cerebral palsy in the 7MM in 2023, including about 1.8 million diagnosed cases. This figure is expected to increase during the study period from 2020 to 2034. In 2023, the US reported the largest number of diagnosed cerebral palsy cases within the 7MM, totaling nearly 932 thousand, which accounts for about 53% of all cases in these areas. In 2023, the UK recorded the highest number of diagnosed cerebral palsy cases among the EU4 and the UK, with about 142 thousand cases, followed closely by Germany with nearly 134 thousand cases. In contrast, Italy had the fewest diagnosed cases, totaling around 105 thousand. In 2023, Japan recorded around 221 thousand cases of cerebral palsy, and this figure is projected to change by 2034. In 2023, the breakdown of type-specific cerebral palsy cases in the US included about 755 thousand spastic cases, 26 thousand dyskinetic cases, 24 thousand ataxic cases, 26 thousand hypotonic cases, and nearly 151 thousand cases classified as other or mixed types. These figures are expected to increase over the study period. Key Cerebral Palsy Companies: Ipsen, Abbvie (Allergan), Supernus Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Bundang CHA Hospital, Jazz Pharmaceuticals, Stanford University, Teva Branded Pharmaceutical, Merz Pharmaceuticals GmbH, Rohto Pharmaceutical Co., Ltd., Shionogi, and others Key Cerebral Palsy Therapies: DYSPORT (abobotulinumtoxin A), Botox (Onabotulinum toxin A), MYOBLOC (RimabotulinumtoxinB), VALBENAZINE, AUSTEDO, Erythropoietin, Sativex, Botulinum Toxin type B, TEV-50717, IncobotulinumtoxinA, UDI-001, Oral Glycopyrrolate Liquid, and others The Cerebral Palsy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cerebral Palsy pipeline products will significantly revolutionize the Cerebral Palsy market dynamics. Cerebral Palsy Overview Cerebral Palsy comprises a collection of conditions impacting movement, muscle tone, and posture. The condition arises from damage to the developing brain, typically occurring before birth, which can affect motor function control. Those affected may experience challenges with both voluntary and involuntary movements, leading to unsteady or lax motions. Get a Free sample for the Cerebral Palsy Market Forecast, Size & Share Analysis Report: Cerebral Palsy Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Cerebral Palsy Epidemiology Segmentation: The Cerebral Palsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving Cerebral Palsy epidemiology trends @ Cerebral Palsy Epidemiology Forecast Cerebral Palsy Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cerebral Palsy market or expected to get launched during the study period. The analysis covers Cerebral Palsy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Cerebral Palsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Cerebral Palsy Therapies and Key Companies Discover more about therapies set to grab major Cerebral Palsy market share @ Cerebral Palsy Treatment Landscape Cerebral Palsy Market Strengths Stem cell therapy is a novel treatment for Cerebral Palsy compared with symptomatic standard care has shown a significant positive effect on gross motor function. Short term safety is present, and further investigations are ongoing. Cerebral Palsy Market Opportunities Due to increasingly compelling evidence that Cerebral Palsy can have a genetic component, studies are testing interventions such as deep brain stimulation (DBS) and personalized medicine for the treatment of patients with Cerebral Palsy. Scope of the Cerebral Palsy Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Cerebral Palsy Companies: Ipsen, Abbvie (Allergan), Supernus Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Bundang CHA Hospital, Jazz Pharmaceuticals, Stanford University, Teva Branded Pharmaceutical, Merz Pharmaceuticals GmbH, Rohto Pharmaceutical Co., Ltd., Shionogi, and others Key Cerebral Palsy Therapies: DYSPORT (abobotulinumtoxin A), Botox (Onabotulinum toxin A), MYOBLOC (RimabotulinumtoxinB), VALBENAZINE, AUSTEDO, Erythropoietin, Sativex, Botulinum Toxin type B, TEV-50717, IncobotulinumtoxinA, UDI-001, Oral Glycopyrrolate Liquid, and others Cerebral Palsy Therapeutic Assessment: Cerebral Palsy current marketed and Cerebral Palsy emerging therapies Cerebral Palsy Market Dynamics: Cerebral Palsy market drivers and Cerebral Palsy market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Cerebral Palsy Unmet Needs, KOL's views, Analyst's views, Cerebral Palsy Market Access and Reimbursement Table of Contents 1. Cerebral Palsy Market Report Introduction 2. Executive Summary for Cerebral Palsy 3. SWOT analysis of Cerebral Palsy 4. Cerebral Palsy Patient Share (%) Overview at a Glance 5. Cerebral Palsy Market Overview at a Glance 6. Cerebral Palsy Disease Background and Overview 7. Cerebral Palsy Epidemiology and Patient Population 8. Country-Specific Patient Population of Cerebral Palsy 9. Cerebral Palsy Current Treatment and Medical Practices 10. Cerebral Palsy Unmet Needs 11. Cerebral Palsy Emerging Therapies 12. Cerebral Palsy Market Outlook 13. Country-Wise Cerebral Palsy Market Analysis (2020–2034) 14. Cerebral Palsy Market Access and Reimbursement of Therapies 15. Cerebral Palsy Market Drivers 16. Cerebral Palsy Market Barriers 17. Cerebral Palsy Appendix 18. Cerebral Palsy Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
